# Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial

Study · id `cardio:ct-nct04948749` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04948749](<https://clinicaltrials.gov/study/NCT04948749>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04948749

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 358 participants.

## Technical summary

Registry record NCT04948749. Randomized; single masking; primary purpose treatment. Start 2021-07-02 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 358 participants (planned count; ClinicalTrials.gov record NCT04948749, source copy `cardio:ctgov-nct04948749-2026-07-15`, retrieved 2026-10-26)
- Started: 2021-07-02 (actual) (ClinicalTrials.gov record NCT04948749, source copy `cardio:ctgov-nct04948749-2026-07-15`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT04948749, source copy `cardio:ctgov-nct04948749-2026-07-15`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT04948749, source copy `cardio:ctgov-nct04948749-2026-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04948749, source copy `cardio:ctgov-nct04948749-2026-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04948749-2026-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
- Acronym: DREAM-PRIDE
- Condition: ICAD - Intracranial Atherosclerotic Disease
- Condition: ICAS - Intracranial Atherosclerosis
- Condition: Drug-eluting Stent
- Condition: Stroke
- Condition: Drug Eluting Stents (DES)
- Condition: Medical Treatment
- Intervention (Device): Drug Eluting Stent implantation
- Intervention (Drug): Aggressive medical treatment
- Intervention (Behavioral): Risk factor management
- Intervention (Drug): Standard medical treatment
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: b5af00fbe14e000cc55c86b5acb7add87f8da7a4c20b2bd207c94eee5b8d33d8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
